Abstract
Why it may no longer be necessary for companies to commission dedicated facilities
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hill, D. and Beatrice, M. 1989. Facility requirement for biotech plants. Pharmaceutical Engineering 9: 35–41.
Hill, D. and Beatrice, M. 1989. Biotechnology facility requirements, part 1: facility and systems design. BioPharm 2: 20–26.
Hill, D. and Beatrice, M. 1989. Biotechnology facility requirements, part 2: Operating procedure and validation. BioPharm 2: 28–32.
Anon. 1990. Biotechnology in the US Pharmaceutical Industry. North Carolina Biotechnology Center. Box 13547, Research Tri angle Park, NC 27709 U.S.
Anon. 1992. Market Letter. April 6: 15.
Anon. 1991. Scrip 1669: 24.
DiMasi, J.A. et al. 1991. Cost of innovation in the pharmaceutical industry. J. Health Economics 10: 107–142.
Anon. 1990. Biotech 90: Into the Next Decade. Ernst & Young, San Francisco.
Longman, R. 1991. Strategic alliances: The alternative option. Pharmaceutical Manufacturing International, Barber, M.S. and Barnacal, P.A., eds., pp. 23–28, Sterling Publ. Int Ltd.
Bader, F.G. et al. 1992. Multiuse manufacturing facilities for biologicals. BioPharm September: 32–40.
Anon. 1986. NIH Guidelines for Research Involving Rccombinant DNA Molecules. U.S. Government Printing Office, Washington, D.C.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hamers, M. Multiuse Biopharmaceutical Manufacturing. Nat Biotechnol 11, 561–570 (1993). https://doi.org/10.1038/nbt0593-561
Issue Date:
DOI: https://doi.org/10.1038/nbt0593-561
